Report : North America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
The oncology segment by therapeutic area is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Therapeutic Area, Technology and Country.” The North America next-generation antibody market is expected to reach US$ 5,428.80 million by 2028 from US$ 2,457.09 million in 2021. It is estimated to grow at a CAGR of 12.0% from 2021 to 2028. The report highlights trends prevailing in the North America mobile next-generation antibody market and the factors driving market along with those that act as hindrances.
Cancer has emerged as a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth leading cause of death in 123 countries worldwide in 2019. The rising prevalence of cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~27.5 million by 2040. The disease is likely to cause ~163 million deaths by that year. Factors, such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions, are expected to increase the burden of cancer patients in several parts of the world in the coming years. Therefore, it is essential to control the increasing number of cancer patients worldwide.
Various governments have initiated programs and initiatives to increase the preventive measures and treatment for cancers. For instance, in 2017, World Health Assembly approved the Resolution Cancer (WHA70.12)—an integrated approach to prevent and control cancer. The program has been appealing to the WHO and various governments to accelerate their efforts to achieve the targets that are specified in the Global Action Plan (2013–2020) for the prevention and control of noncommunicable diseases (NCDs) and the 2030 UN Agenda for Sustainable Development to reduce early deaths from cancer. In addition, various private organizations have joined the action plans to prevent the increasing burden of cancer, creating a demand for better preventive measures against the disease. Thus, the rising prevalence of cancer has accelerated the need for new and effective therapeutic approaches, such as next-generation antibodies, boosting the market.
North America is highly affected due to the outbreak of the COVID-19 pandemic. The US-registered highest number of deaths due to the COVID-19 pandemic. The outbreak has put an immense burden on healthcare infrastructure in the US, Canada, and Mexico. Most pharmaceutical and biotechnological companies and research institutes are involved in developing COVID-19 vaccines and drugs.
Both established pharmaceutical companies and small startups have come forward to advance treatments and vaccines that target the infection created by the novel coronavirus. As a result, vaccine-related research activities in pharmaceutical and biotechnology companies, research centers, and educational research institutes are acknowledged essential and have been primarily unaffected in operations and output. However, due to the rise in research activities, the accessibility of funding for analysis and the need for antibodies, including next-generation antibodies, is anticipated to grow over the next few years.
Many researchers worldwide are involved in the viral examination of SARS-CoV-2, which develops COVID-19. Antibodies generated for both vaccines and therapeutics are examined to counterbalance the target virus for their functional efficiency.
The approval of monoclonal antibody services has increased for the development of COVID-19 vaccines. Companies engaging in the next-generation antibody market witnessed a negative impact on their services in early 2020 due to the temporary shutdown of their laboratories. However, as lockdown limitations were gradually lifted, research laboratories worldwide started reopening. As a result, most service providers prioritized actions to promote the critical work, such as giving a range of high-quality COVID-19-related research tools, reassigning R&D resources for producing essential products for SARS-Cov-2, expanding the supply chain, and supporting the augmented demand for long-term products required for SARS-CoV-2/COVID-19 research. They also focused on entering into discussions and collaborations concentrated on SARS-CoV-2 diagnostics, drugs, and vaccines development across the UK, the US, and China. Considering these factors, it can be declared that the impact of COVID-19 on the next-generation antibody market has been positive. Therefore, the COVID-19 pandemic is expected to aid the North America next-generation antibody market during the forecast period.
Based on therapeutic area, the North America next-generation antibody market has been segmented into oncology and autoimmune or inflammatory. Based on application, the North America market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. Geographically, the North America next-generation antibody market is sub-segmented into U.S, Canada and Mexico.
F. HOFFMANN-LA ROCHE LTD., Kyowa Kirin Co., Ltd., Seagen Inc., ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Pfizer Inc., Catalent Inc, AstraZeneca and Xencorare among the leading companies operating in the North America next-generation antibody market.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org